Company updateCNBC-TV18
Caplin Point US own-label sales to double by 2026-27
Positive+39
GreyOak summary
Caplin Point Laboratories expects its US own-label business to more than double to approximately ₹200 crore by the end of 2026-27. The company, which is debt-free with ₹1,500 crore in cash, is expanding into Mexico and oncology while keeping acquisition options open. Latin America currently contributes nearly 80% of its revenues.
What it affects
- Caplin Point LaboratoriesCAPLIPOINTPositive +39
US own-label sales expected to double by 2026-27.Rolling sentiment Negative -15
Source
Read the original at CNBC-TV18More Caplin Point Laboratories news
- Caplin Point Q2 revenue up 18%, stock falls 6%CNBC-TV18 · Results ·